Analyst Reco. Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Real-time Estimate Cboe BZX Other stock markets 12:53:44 2024-04-30 EDT			5-day change	1st Jan Change
19.42 ^USD	-1.92%		+4.62%	+1.67%

03-20	Myriad Genetics Gets US Patent for SneakPeek Snap Device	MT
02-27	Transcript : Myriad Genetics, Inc., Q4 2023 Earnings Call, Feb 27, 2024

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Goldman Sachs Adjusts Myriad Genetics' Price Target to $31 From $28, Maintains Buy Rating	01-29	MT
BofA Securities Adjusts Price Target on Myriad Genetics to $20 From $18, Maintains Underperform Rating	01-29	MT
Wells Fargo Initiates Myriad Genetics at Equalweight Rating With $20 Price Target	12-19	MT
Wolfe Research Initiates Myriad Genetics With Outperform Rating With $28 Price Target	12-13	MT
BofA Securities Trims Price Target on Myriad Genetics to $18 From $21, Maintains Underperform Rating	23-10-20	MT
JPMorgan Adjusts Myriad Genetics' Price Target to $17 From $18, Keeps Underweight Rating	23-08-07	MT
Goldman Sachs Adjusts Price Target on Myriad Genetics to $28 From $25, Maintains Buy Rating	23-07-21	MT
Goldman Sachs Upgrades Myriad Genetics to Buy From Sell, Raises Price Target to $25 From $18	23-05-23	MT
ANALYST RECOMMENDATIONS : Chevron, Deere & Co, Nvidia, Steel Dynamics...	23-05-23
Jefferies Raises Myriad Genetics' Price Target to $22 From $19, Hold Rating Kept	23-05-04	MT
Morningstar Downgrades Myriad Genetics to Sell From Hold, $18.50 Price Target	23-05-04	MT
Goldman Sachs Cuts Myriad Genetics' Price Target to $18 From $20, Sell Rating Kept	23-05-04	MT
Stephens Adjusts Price Target on Myriad Genetics to $24 From $17, Maintains Equal-Weight Rating	23-03-06	MT
Raymond James Adjusts Price Target on Myriad Genetics to $27 From $25, Maintains Outperform Rating	23-03-03	MT
Raymond James Upgrades Myriad Genetics to Outperform From Market Perform, Price Target is $25	23-01-18	MT
SVB Securities Adjusts Price Target on Myriad Genetics to $25 From $27, Maintains Market Perform Rating	22-11-02	MT
Stephens Starts Myriad Genetics at Equalweight With $22 Price Target	22-10-06	MT
MYRIAD GENETICS : Raymond James Initiates Coverage on Myriad Genetics With Market Perform Rating	21-06-15	MT
MYRIAD GENETICS : Goldman Sachs Starts Myriad Genetics at Sell With $25 Price Target	21-06-03	MT
MYRIAD GENETICS : JP Morgan Adjusts Price Target for Myriad Genetics to $20 From $12, Maintains Underweight Rating	21-02-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Myriad Genetics, Inc.

Equities

MYGN

US62855J1043

Analyst Reco.

Filters